1512559-37-3

1512559-37-3 structure

1512559-37-3 structure

Name: Elgemtumab
Chemical Name: Elgemtumab
CAS Number: 1512559-37-3
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways JAK/STAT Signaling EGFR
Create Date: 2023-03-11 10:44:36
Modify Date: 2023-03-11 10:44:36
Elgemtumab(LJM716) is a fully human IgG monoclonal antibody. Elgemtumab can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor potential[1].

Name	Elgemtumab

Description	Elgemtumab(LJM716) is a fully human IgG monoclonal antibody. Elgemtumab can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor potential[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> JAK/STAT Signaling >> EGFR Signaling Pathways >> Protein Tyrosine Kinase/RTK >> EGFR
In Vivo	Elgemtumab(LJM716)(i.v., 20 mg/kg,once)在 BT474 乳腺癌异种移植物的 SCID 小鼠中，可以使 pHER3 最大减少 52%，pAKT 最大减少 84 %；而在 BxPC-3 胰腺异种移植物的 SCID 小鼠中，导致 pHER3 的最大抑制为 86%，pAKT 的最大抑制为 74%[1]。 Elgemtumab(LJM716)(20 mg/kg, every other day, 35 days)在 BT474 乳腺癌异种移植物的 NSG 小鼠中，可以减缓肿瘤生长[1]。
References	[1]. Andrew P Garner, et al. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res. 2013 Oct 1;73(19):6024-35.

No Any Chemical & Physical Properties